Professor Alison Grant
Professor of International Health, London School of Hygiene & Tropical Medicine
Honorary Professor: School of Public Health, University of the Witwatersrand
Honorary Consultant in HIV Medicine:Mortimer Market Centre, London.
Department of Clinical Research
London School of Hygiene & Tropical Medicine
London WC1E 7HT
T. +44 20 7927 2304
1.Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, Erasmus LK, Ndjeka N, Mvusi L, Vassall A, Sinanovic E, Cox HS, Dye C, Grant AD, Fielding KL. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015;3:e450-457.
2. Getahun H, Matteelli A, Abubakar I, Abdel Aziz M, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015 (in press)
3. Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant AD, Churchyard GJ, Watts C, Vickerman P. The impact of company-level ART provision to a mining workforce in South Africa: A cost-benefit analysis. PLoS Med 2015;12(9): e1001869.
4. Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, Corbett EL, Churchyard GJ, Grant AD, White RG. Tuberculosis control in South African goldmines: mathematical modelling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol 2015;181:619-32.
5. Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, Hayes RJ, Chaisson RE, Grant AD. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014;370:301-310.
6. Houben R, Sumner T, Grant AD, White RG. The ability of preventive therapy to cure latent M. tuberculosis infection in HIV-infected individuals in high burden settings Proc Natl Acad Sci USA 2014;111:5325-30.
7. Johnston V, Cohen K, Weisner L, Morris L, Ledwaba J, Fielding K, Charalambous S, Churchyard G, Phillips A, Grant AD. Viral suppression following switch to second-line antiretroviral therapy: the association with NRTI resistance and ‘sub-therapeutic’ drug concentrations prior to switch. J Infect Dis 2014;209:711-20.
8. Hoffmann CJ, Lewis JJ, Dowdy DW, Fielding KL, Grant AD, Martinson NA, Churchyard GJ, Chaisson RE. Mortality associated with delays between clinic entry and ART initiation in resource-limited-settings: results of a transition-state model. J Acquir Immune Defic Syndr 2013;63:105-111.
9. Legido-Quigley H, Montgomery CM, Khan P, Atun R, Fakoya A, Getahun H, Grant AD. Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health 2013;18:199-211.
10. Johnston VJ, Fielding KL, Charalambous S, Churchyard G, Philips A, Grant AD. Outcomes Following Virological Failure and Predictors of Switching to Second-line Antiretroviral Therapy in a South African Treatment Programme. J Acquir Immune Defic Syndr 2012;61:370-380.
11. Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, Chaisson RE, Grant AD, Churchyard GJ. Changing predictors of mortality over time from cART start in Africa: implications for care. J Acquir Immune Defic Syndr 2011;58:269-276.
12. Getahun H, Kittikraisak W, Heilig CM, Corbett E, Ayles H, Cain KP, Grant AD, Churchyard G, Kimerling M, Shah S, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011;8(1):e1000391.
13 Churchyard GJ, Fielding K, Roux S, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Grant AD. 12- versus 6-monthly radiological screening for the active case-finding of tuberculosis: a randomised controlled trial. Thorax 2011;66:134-9.
Alison Grant’s research interest is evidence-based care for HIV-positive people in resource-limited settings, particularly the development and evaluation of interventions to reduce morbidity and mortality due to tuberculosis.
Since 1997, Alison’s research has focused on the intersection between HIV and tuberculosis in South Africa. She took up leadership of the new TB programme at the Africa Centre for Population Health in 2014.
Recent major projects:
- TB Fast Track, a cluster-randomised trial in 24 primary care clinics in South Africa aiming to reduce early mortality on antiretroviral therapy by improving detection and early treatment of active tuberculosis, funded by DfID/MRC/Wellcome Trust Global Health Trials.
- XTEND: a cluster-randomised trial evaluating South African national roll-out of the new tuberculosis diagnostic test Xpert MTB/RIF, primarily its impact on mortality among people being investigated for tuberculosis, funded by the Bill and Melinda Gates Foundation.
- XPHACTOR: an interventional cohort study investigating how to prioritise TB investigation among HIV clinic attendees, funded by the Bill and Melinda Gates Foundation.
- Lesedi Kamoso: a study nested within TB Fast Track, XTEND and XPHACTOR, investigating causes of death and comparing minimally invasive autopsy with verbal autopsy, funded by the Bill and Melinda Gates Foundation.
- RR linkage study: a retrospective cohort study investigating linkage to care among people found to have rifampicin resistance on testing with Xpert MTB/RIF in South Africa, funded by the Bill and Melinda Gates Foundation.
- Thibela TB: a cluster-randomised trial of mass screening and isoniazid preventive therapy (IPT) for tuberculosis control involving 80,000 gold miners, funded primarily by the Bill and Melinda Gates Foundation.